

Figure S1.

The stress predominantly affects the first phase of heart regeneration.

(A-K) Heart sections at 60 dpci after AFOG staining were analyzed in the same manner as described in Fig. 2. After cryoinjury, zebrafish were subjected to daily stress either during the whole period of 60 days (crowding: C-E) or only during the first 30 days (crowding: F-H; heat shock: I-L). (L-P) Heart sections at 30 dpci after AFOG staining. In this case, zebrafish were exposed to daily crowding either during the first 2 weeks (L-N) or during the final 2 weeks (O, P). (L-N) The cryoinjured hearts of fish that were stressed for the first 2 weeks followed by 2 weeks of recovery at normal conditions display impaired regeneration. 78% of the animals displayed a partial or complete blockage of heart regeneration. (O, P) The cryoinjured hearts of fish that were kept at normal conditions for the first 2 weeks and then exposed to stress for the final 2 weeks, regenerated the hearts. The analysis of the regenerative process in the different groups revealed that daily exposure to stress has a stronger impact on the initial phase of heart regeneration. (Q) Analysis of the body weights before cryoinjuries and at 30 dpci revealed no significant weight changes during this period in control and stressed animals. (R) Glucose measurements revealed higher levels of blood glucose in the control animals as compared to stressed fish at 30 dpci. $N \geq 8$. No difference was observed at 7 dpci. Data are represented as mean \pm SEM. $**P < 0.01$; $N=5$. Scale bar (A) = 100 μm .





Figure S2.

Rapid cardiac growth is affected by daily acute stress exposure.

(A, B) Sections of hearts of control and stressed zebrafish 10 days after the transfer to low density conditions (3 fish / 10 liters) stained with antibodies against Tropomyosin (TPM, red), MCM5, a G1/S-phase marker (green) and with DAPI (blue). Juvenile zebrafish (2 months of age) were exposed 2 x per day to crowding (10 fish/ 250ml during 1h) during 10 days to investigate the effect of stress on cardiac homeostatic growth. (A', B') Higher magnifications of the framed area shown in (A, B). A higher number of proliferating cardiac cells (CMs and non CMs) were identified in the control fish when compared to the stressed animals (arrows). (C) Bar graphs show the percentage of proliferating cells (MCM5-positive DAPI-positive / DAPI-positive in the tropomyosin-labeled myocardium) in the animals maintained at high density (5 fish per liter) and in control and stressed animals transferred to low density conditions (3 fish in 10 liters). Ventricles exposed to daily stress (10 fish/ 250 ml, 2 x 1h/day) showed a significantly lower proportion of proliferating cardiac cells than control hearts. (D) Bar graphs show the average weight of the animals at day 0, after 10 days in high density conditions (3 fish in 1 liter), after 10 days in low density conditions (3 fish in 10 liters) and after 10 days in low density conditions with daily exposure to crowding (10 fish/ 250 ml, 2 x 1h/day). Data are represented as mean \pm SEM. *P < 0.05, **P < 0.01 ***P < 0.001, ****P < 0.0001; N \geq 4.




Figure S3.

The concomitant administration of dexamethasone and adrenaline after cryoinjury mimics the effect of stress on heart regeneration.

(A, B) Representative images of cryoinjured hearts at 30 dpci labeled with phalloidin (red, F-actin), dapi (blue) and antibody against L-Plastin (green, leukocytes). (A', B') Higher magnification of the frame areas shown in (A, B). (C) Quantification of L-Plastin-positive area normalized to the total area of the ventricles revealed no significant effect of daily acute dexamethasone (2 mg/l) treatment on cardiac inflammation. $N > 4$. (D-M) Sections of hearts at 30 days post cryoinjury (dpci) after Anilin blue acid Fuchsin Orange-G (AFOG). (F-M) The acute administration (1 hour per day) of dexamethasone (Dex, 2 mg/l) alone (H-J) or concomitantly with adrenaline (adr, 1 mg/l) (K-M) resulted in cardiac regenerative impairment in 50% and 62.5% of the fish, respectively. In contrast, animals treated with adrenaline alone during 1 hour per day displayed similar regenerative scores as the control (D-G). (N-P) Heart sections of *cm1c2::dsRed2-Nuc* transgenic zebrafish at 7 dpci immunostained against MCM5 (green). (N'-P') Higher magnification of the framed areas shown in (N-P). Proliferating CMs could be identified in all groups by the overlap between MCM5 and DsRed (arrowheads). In contrast to adrenaline (1 mg/l, 1h /day), the treatment with glucocorticoid (hydrocortisone, 1 mg/l) lead to a reduction in CM proliferation at 7 dpci. Cryoinjured parts are encircled with a dashed line. Scale bar (A, D, N) = 100 μ m.




Figure S4.

Propranolol and fluoxetine hydrochloride administration have a beneficial effect on cardiac regeneration in the stressed animals.

(A-L) Heart sections at 30 dpci after AFOG staining. (E-L) The treatment of the stressed animals with propranolol (1 mg/l, 1 h/day, 3 days pretreatment, H, I) and fluoxetine hydrochloride (100 µg /l, continuous, 2 weeks pretreatment, J-L) had a significant rescue effect on the stress-induced regenerative impairment whereas the administration of diazepam (1 mg/l, continuous, 3 days pretreatment, E-G) did not rescue the negative effect of stress on heart regeneration. Scale bar (A) = 100 µm.




Figure S5.

Modulation of the stress response: effect on cardiac regeneration.

In zebrafish, exposure to different stressors activates two main axes: (1) the hypothalamus-pituitary interrenal (HPI) axis (green) and (2) the sympathetic-chromaffin cell axis (purple).

The treatment of the stressed animals after cryoinjury with fluoxetine hydrochloride (serotonin re-uptake inhibitor) and propranolol (non-selective β -adrenoreceptor antagonist) had a significant rescue effect on the stress-induced regenerative impairment. The administration of diazepam (GABA_A receptor enhancer) did not show any beneficial effect on scar resorption. The intermittent administration of RU486 (glucocorticoid antagonist) did not rescue cardiomyocyte proliferation in the stressed animals and the prolonged treatment with this drug was toxic and resulted in a high lethality.




Figure S6.

Epi/endocardium activation, Tenascin C expression and cellular apoptosis are not affected by daily exposure to stress.

(A-D) Sections of *cm1c2::dsRed2-Nuc* hearts of control and stressed zebrafish at 14 dpci immunostained against the retinoic acid synthesizing enzyme (Raldh2, green), which is a marker of the activated epi-endocardium (A, B) or against Tenascin C (TNC, green), which is an ECM protein involved in tissue remodeling (C, D). (A'-D') Higher magnifications of the framed areas shown in (A-D). Expression of the Raldh2 enzyme and Tenascin C could be detected at the injured site and in the epicardium both in control (A', C') and stressed (B', D') fish. This indicates no major impact of daily stress on epicardial/endocardial activation or on Tenascin C regulation. Scale bar (D, D') = 100 μ m.

(E, F) Sections of *cm1c2::dsRed2-Nuc* hearts at 7 dpci after TUNEL assay and DAPI staining. (E', F') Apoptotic cells were detected by signal overlap between TUNEL and DAPI in the cryoinjured parts but also in the rest of the ventricle. (G) Quantification of TUNEL and DAPI positive cells allowed to estimate the level of cellular apoptosis in the ventricle of the control and crowded zebrafish. No significant difference in apoptosis was observed between control and stressed fish at 7 dpci. Cryoinjured parts are encircled with a dashed line. Data are represented as mean \pm SEM. Scale bar (F, F') = 100 μ m.




Figure S7. Experimental setup for the RNA-seq1 & 2 experiments and principal components analysis of both experiments.

(A) Experimental setup for the RNA sequencing 1 performed at 14 dpci with the RNA extracted from the cryoinjured parts of the stressed and control hearts. (B, C) The use of *cmlc2::EGFP-PM* transgenic zebrafish, expressing GFP in the plasma membrane of CMs, enabled to identify and isolate the cryoinjured parts of the ventricle used for the RNA-sequencing experiment (15 cryoinjured parts were pulled together for each group in order to get sufficient amount of RNA). (D) Experimental setup for the RNA sequencing 2 performed at 14 dpci with the RNA extracted from the wholes ventricles of the stressed and control hearts. (E) Principal component analysis plot performed with RNA-seq1 and RNA-seq2. The Principal Component Analysis (PCA) is a classical method of statistical analysis. By transforming the set of observations into linearly uncorrelated variables called "principal component". By definition the PCs are ordered by the variance they can explain in the data. PC1 explains the largest variance, then PC2, then PC3 etc. In our experiment, PC1 allows discriminating the two independant RNAseq experiments, and PC2 discriminates the stress and the control samples in both RNAseq experiments. Scale bar (B)= 100 μ m.





Figure S8.

Inhibition of IGF-1 receptor impairs heart regeneration.

(A-F) Heart sections at 30 dpcl after AFOG staining. (A-C) In the control group treated with 0.05% DMSO, 66% of the zebrafish completely regenerated the heart at 30 dpcl. (D-F) In the group treated with NVP-ADW742 (5 µM), a specific inhibitor of the Igf1r kinase activity, 62.5% of the fish showed impaired cardiac regeneration at 30 dpcl. (G) Histograms represent the percentage of zebrafish hearts with complete (white), partial (gray) or blocked (black) regeneration at distinct experimental settings (regenerative scores). Scale bar (A) = 100 µm.

| Name | # of Entities | Expanded # of Entities | # of Measured Entities | Median change | p-value | Hit type |
|--|---------------|------------------------|------------------------|---------------|------------|-----------------------------|
| Proteins Involved in Pathogenesis of Melanoma | 245 | 262 | 180 | 1.121233899 | 5.5849E-06 | Disease Collections |
| Built Pathway_IGFBP1b_downstream cell processes | 178 | 763 | 238 | 1.086427761 | 2.7121E-05 | Private pathways |
| Proteins Involved in Pathogenesis of Glioma | 304 | 340 | 207 | 1.083054452 | 2.8003E-05 | Disease Collections |
| Defective Clearance of Apoptotic Keratinocytes in Systemic Lupus Erythematosus | 79 | 245 | 89 | 1.071944531 | 2.9092E-05 | Disease Collections |
| BMP7-ACVR2 Expression Targets | 27 | 29 | 21 | 1.610822919 | 0.00026135 | Expression Targets Pathways |
| TGFB1-ACVRL1 Expression Targets | 221 | 233 | 138 | 1.175402723 | 0.00028927 | Expression Targets Pathways |
| EGF/CTNN Expression Targets | 143 | 156 | 96 | 1.279815128 | 0.00032076 | Expression Targets Pathways |
| B Cell Activation | 62 | 841 | 506 | 1.181790244 | 0.00032227 | Cell Signaling |
| TLR4/NF-kB/IRF Expression Targets | 70 | 76 | 37 | 1.07553905 | 0.00034869 | Expression Targets Pathways |
| Pathway_Genes_Imp | 954 | 954 | 628 | 1.033202234 | 0.00037041 | Private pathways |
| B-cell Chronic Lymphocytic Leukemia Overview | 122 | 430 | 273 | 1.258365961 | 0.0003856 | Disease Collections |
| Extracellular Matrix Turnover | 36 | 166 | 76 | 1.228851937 | 0.00039486 | Cell Process Pathways |
| Melanoma Overview | 176 | 627 | 429 | 1.131958925 | 0.00043896 | Disease Collections |
| EphrinR -> actin signaling | 15 | 216 | 141 | -1.020568772 | 0.00051062 | Receptor Signaling |
| Dystrophin Glycoprotein Complex Signaling in Duchenne Muscular Dystrophy | 67 | 792 | 490 | 1.151354255 | 0.00054743 | Disease Collections |
| OXIDATIVE(ROS)Dystrophin Glycoprotein Complex Signaling in Duchenne Mus | 67 | 792 | 490 | 1.151354255 | 0.00054743 | Private pathways |
| Proteins Involved in Pathogenesis of Glioblastoma | 188 | 210 | 138 | -1.044766759 | 0.00055643 | Disease Collections |
| Hodgkin Lymphoma Overview | 146 | 614 | 285 | 1.254934272 | 0.00062251 | Disease Collections |
| TLR4 -> IRF signaling | 14 | 14 | 10 | 1.837768696 | 0.0007392 | Receptor Signaling |
| TGFB1-TGFBR1 Expression Targets | 89 | 91 | 47 | 1.269441599 | 0.00076762 | Expression Targets Pathways |
| Proteins Involved in Pathogenesis of Cataract | 95 | 95 | 53 | 1.106356331 | 0.00099064 | Disease Collections |
| Role of Hexosamine Pathway in Diabetic Microangiopathy | 26 | 145 | 71 | 1.1450458 | 0.0009942 | Disease Collections |
| T Cell Activation | 80 | 948 | 471 | 1.033202234 | 0.00101336 | Cell Signaling |
| PDGF/STAT Expression Targets | 80 | 89 | 57 | 1.164725658 | 0.00102698 | Expression Targets Pathways |
| Proposed Mechanisms of Antiepileptic Effects of a Ketogenic Diet | 56 | 365 | 219 | 1.285492956 | 0.00108017 | Disease Collections |
| Atlas of Signaling | 381 | 6035 | 3424 | 1.083054452 | 0.00113812 | Cell Signaling |
| Insulin/CEBPA/CTNNB/FOXA/FOXO Expression Targets | 145 | 171 | 109 | -1.019580018 | 0.00129622 | Private pathways |
| Insulin/CEBPA/CTNNB/FOXA/FOXO Expression Targets | 145 | 171 | 109 | -1.019580018 | 0.00129622 | Expression Targets Pathways |
| Notch_Insulin/CEBPA/CTNNB/FOXA/FOXO Expression Targets | 145 | 171 | 109 | -1.019580018 | 0.00129622 | Private pathways |
| Cell Cycle Regulation | 135 | 2176 | 1436 | 1.13136165 | 0.00135125 | Cell Signaling |
| Common Non-genomic Effects of Thyroid Hormones | 60 | 338 | 195 | -1.020568772 | 0.00140719 | Disease Collections |
| BMP2 Activates WNT Signaling in Pulmonary Artery Smooth Muscle Cells | 26 | 253 | 163 | -1.028555619 | 0.00154104 | Disease Collections |
| TGFB1-TGFBR2 Expression Targets | 116 | 125 | 77 | 1.205982884 | 0.00157163 | Expression Targets Pathways |
| Actomyosin-Based Movement | 25 | 85 | 31 | -1.305557659 | 0.00160695 | Cell Process Pathways |
| Actin Cytoskeleton Regulation | 51 | 546 | 369 | 1.030942621 | 0.00179848 | Cell Signaling |
| Ca2+ Overload in Duchenne Muscular Dystrophy | 59 | 256 | 150 | 1.033202234 | 0.00184601 | Disease Collections |
| Role of HMGB1 and IL1B in Neuroinflammation in Epilepsy | 25 | 29 | 19 | -1.115450282 | 0.00186536 | Disease Collections |
| TNF/NF-kB Expression Targets | 127 | 135 | 68 | 1.164725658 | 0.00192162 | Expression Targets Pathways |
| INHBA-ACVR2/ACVR1 Expression Targets | 25 | 27 | 20 | 1.610822919 | 0.00193913 | Expression Targets Pathways |
| T-cell Receptor Signaling | 71 | 371 | 203 | -1.00209964 | 0.00194978 | Immunological Pathways |
| Onset of Atopic Dermatitis | 72 | 343 | 203 | -1.00209964 | 0.00194978 | Disease Collections |
| IL1B Expression Targets | 169 | 195 | 109 | 1.0215013 | 0.00196439 | Expression Targets Pathways |
| Vascularization in Hepatocellular Carcinoma | 25 | 101 | 52 | 1.077367242 | 0.00203218 | Disease Collections |
| Secondary Glioblastoma | 66 | 343 | 237 | 1.258365961 | 0.00204329 | Disease Collections |
| ROS metabolism | 45 | 108 | 16 | 1.888036854 | 0.00217801 | Metabolic Pathways |
| EGF/MEF/MYOD/NFATC Expression Targets | 145 | 231 | 138 | 1.03973094 | 0.00222991 | Expression Targets Pathways |
| Leptin/STAT Expression Targets | 96 | 107 | 63 | 1.194807312 | 0.00239132 | Expression Targets Pathways |
| AGT/CREB Expression Targets | 116 | 193 | 110 | 1.094417435 | 0.00244381 | Expression Targets Pathways |
| Vitamin A (retinol) metabolism and visual cycle | 93 | 165 | 19 | 1.22335471 | 0.00261586 | Metabolic Pathways |
| Sister Chromatid Cohesion | 27 | 174 | 113 | 1.317461315 | 0.00276692 | Cell Process Pathways |

Table S1.

Gene set enrichment analysis for the the fused RNA seq experiment (RNA-seq1&2) to highlight changes in gene expression between control and stressed zebrafish hearts. The table shows the 50 most significant **pathway** gene sets for the fused RNA-seq experiment: RNA-seq1 & RNA-seq2. The analysis was performed with Pathway Studio.

| Name | # of Entities | Expanded # of Entities | # of Measured Entities | Median change | p-value | Hit type |
|--|---------------|------------------------|------------------------|---------------|------------|--------------------|
| SRP-dependent cotranslational protein targeting to membrane | 108 | 108 | 74 | 1.77234506 | 3.0145E-10 | biological_process |
| viral transcription | 82 | 82 | 56 | 1.84158913 | 4.4373E-10 | biological_process |
| translational termination | 89 | 89 | 62 | 1.7790759 | 1.112E-08 | biological_process |
| viral life cycle | 93 | 93 | 63 | 1.77234506 | 4.2407E-08 | biological_process |
| translational elongation | 149 | 149 | 74 | 1.76277199 | 3.1223E-07 | biological_process |
| cell adhesion | 658 | 658 | 342 | 1.03973094 | 1.4525E-06 | biological_process |
| response to virus | 145 | 145 | 68 | 1.37681504 | 1.67E-06 | biological_process |
| cytosolic large ribosomal subunit | 68 | 68 | 33 | 1.7790759 | 1.7438E-06 | cellular_component |
| actin binding | 395 | 395 | 223 | -1.0781643 | 1.789E-06 | molecular_function |
| Z disc | 124 | 124 | 71 | 1.0368129 | 4.4501E-06 | cellular_component |
| extracellular region | 2319 | 2319 | 793 | 1.10562778 | 1.0497E-05 | cellular_component |
| cytosol | 2752 | 2752 | 1886 | 1.1016447 | 1.3491E-05 | cellular_component |
| homophilic cell adhesion | 160 | 160 | 47 | -1.1749899 | 1.451E-05 | biological_process |
| nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 122 | 122 | 86 | 1.64589637 | 1.7059E-05 | biological_process |
| extracellular matrix | 250 | 250 | 154 | 1.1450458 | 4.0576E-05 | cellular_component |
| cytosolic small ribosomal subunit | 59 | 59 | 28 | 1.78686236 | 5.2213E-05 | cellular_component |
| proteinaceous extracellular matrix | 318 | 318 | 167 | 1.12703243 | 8.9256E-05 | cellular_component |
| DNA strand elongation involved in DNA replication | 31 | 31 | 21 | 1.87578021 | 0.00011666 | biological_process |
| cytokine binding | 22 | 22 | 11 | 1.66175581 | 0.00011674 | molecular_function |
| structural constituent of muscle | 52 | 52 | 28 | -1.22291476 | 0.00013793 | molecular_function |
| innate immune response | 669 | 669 | 341 | 1.09441743 | 0.0001406 | biological_process |
| structural constituent of ribosome | 416 | 416 | 112 | 1.5427905 | 0.00014143 | molecular_function |
| cellular response to exogenous dsRNA | 14 | 14 | 6 | 2.831489 | 0.00014868 | biological_process |
| myosin complex | 59 | 59 | 35 | -1.37424361 | 0.00019363 | cellular_component |
| heparin binding | 166 | 166 | 75 | 1.10667467 | 0.0001945 | molecular_function |
| collagen binding | 61 | 61 | 42 | 1.36796593 | 0.00020382 | molecular_function |
| inositol phosphate-mediated signaling | 12 | 12 | 6 | -2.02442083 | 0.00022145 | biological_process |
| transmembrane signaling receptor activity | 178 | 178 | 71 | -1.02278562 | 0.00022579 | molecular_function |
| muscle filament sliding | 39 | 39 | 24 | 1.15324394 | 0.00022622 | biological_process |
| positive regulation of neutrophil chemotaxis | 19 | 19 | 11 | 2.51787823 | 0.00022765 | biological_process |
| translational initiation | 149 | 149 | 100 | 1.58878194 | 0.00024611 | biological_process |
| actin filament binding | 97 | 97 | 70 | -1.08544637 | 0.00025982 | molecular_function |
| response to vitamin D | 27 | 27 | 19 | -1.46988038 | 0.00031118 | biological_process |
| protein homodimerization activity | 765 | 765 | 434 | 1.03320223 | 0.00031824 | molecular_function |
| RNA metabolic process | 250 | 250 | 195 | 1.49149742 | 0.00042772 | biological_process |
| cellular response to mechanical stimulus | 86 | 86 | 52 | -1.04631187 | 0.00050118 | biological_process |
| mRNA metabolic process | 227 | 227 | 180 | 1.52096928 | 0.0005202 | biological_process |
| mitotic cell cycle | 394 | 394 | 300 | 1.27847668 | 0.00060125 | biological_process |
| cardiac muscle cell action potential involved in contractile activity | 10 | 10 | 7 | -1.96299321 | 0.00063621 | biological_process |
| positive regulation of potassium ion transport | 16 | 16 | 9 | -1.66351809 | 0.00075449 | biological_process |
| myoblast migration | 5 | 5 | 5 | 2.45266796 | 0.00081209 | biological_process |
| superoxide anion generation | 15 | 15 | 8 | 3.21042632 | 0.00085169 | biological_process |
| immune response | 449 | 450 | 119 | 1.15294089 | 0.00099846 | biological_process |
| regulation of stress fiber assembly | 7 | 7 | 6 | -1.99257912 | 0.00100537 | biological_process |
| cellular amino acid metabolic process | 50 | 50 | 32 | 1.12440149 | 0.00108476 | biological_process |
| viral process | 320 | 320 | 243 | 1.42239843 | 0.00110895 | biological_process |
| cell periphery | 48 | 48 | 28 | 1.09441743 | 0.00116032 | cellular_component |
| regulation of small GTPase mediated signal transduction | 174 | 174 | 108 | -1.11122585 | 0.0012402 | biological_process |
| small ribosomal subunit | 48 | 48 | 18 | 1.72612426 | 0.00128253 | cellular_component |
| energy reserve metabolic process | 103 | 103 | 68 | -1.11351284 | 0.00129081 | biological_process |

Table S2. Gene set enrichment analysis for the fused RNA seq experiment (RNA-seq1&2) to highlight changes in gene expression between control and stressed zebrafish hearts. The table shows the 50 most significant **GO-term** gene sets for the fused RNA-seq experiment: RNA-seq1 & RNA-seq2. The analysis was performed with Pathway Studio.

| geneID | log2FC_fused | padj_fused | type of RNA |
|--------------------|--------------|------------|----------------|
| IFITM1 | 3.742286001 | 1.14E-30 | |
| ENSDARG00000084533 | 3.881034115 | 1.21E-28 | miRNA |
| ENSDARG00000081938 | 8.047716049 | 1.79E-24 | Mt-tRNA |
| SLC25A4 | -2.760180063 | 1.18E-21 | |
| ENSDARG00000088865 | 3.443302383 | 1.18E-21 | miRNA |
| LGALS3BP | 3.113514297 | 1.69E-21 | |
| CORO2A | -5.652379587 | 3.78E-21 | |
| ENSDARG00000088976 | 3.582835203 | 3.15E-20 | miRNA |
| ENSDARG00000086686 | 3.47104141 | 4.73E-20 | miRNA |
| FHL2 | 2.929914201 | 1.73E-19 | |
| ENSDARG00000089384 | 4.183491967 | 1.96E-19 | miRNA |
| ENSDARG00000070212 | 3.256322883 | 1.13E-18 | |
| ENSDARG00000090280 | 3.435020079 | 4.47E-18 | miRNA |
| ENSDARG00000091738 | 3.373336585 | 6.97E-18 | miRNA |
| PARP6 | -2.569819142 | 1.76E-17 | |
| MYBPH | -2.572453077 | 8.25E-17 | |
| ENSDARG00000093902 | 7.612314957 | 3.87E-16 | pseudogene |
| PCOLCE | 2.707511492 | 1.34E-15 | |
| GRIN3A | -4.873753905 | 1.85E-15 | |
| ENSDARG00000087783 | 3.665121865 | 1.85E-15 | miRNA |
| ENSDARG00000088564 | 3.429343718 | 1.85E-15 | miRNA |
| IFI27 | 2.641037412 | 3.49E-14 | |
| ADCY6 | -2.924964698 | 3.70E-14 | |
| CPAMD8 | 3.645294968 | 1.08E-13 | |
| ENSDARG00000089068 | 7.09582739 | 2.01E-13 | pseudogene |
| MIH7B | -2.872828154 | 3.78E-13 | |
| ENSDARG00000090619 | 2.873602128 | 3.78E-13 | miRNA |
| ENSDARG00000086606 | 7.03980247 | 3.78E-13 | pseudogene |
| ENSDARG00000086256 | -2.733709962 | 4.41E-13 | protein_coding |
| CRIP1 | 2.06748148 | 4.84E-13 | |
| GNB3 | -5.560717107 | 5.66E-13 | |
| ENSDARG00000086396 | 2.928302686 | 8.23E-13 | miRNA |
| SEC61G | 2.213266624 | 8.24E-13 | |
| ENSDARG00000086085 | 3.124629975 | 9.25E-13 | miRNA |
| IFI27L1 | 2.450376839 | 1.06E-12 | |
| ENSDARG00000088436 | 2.770051212 | 1.22E-12 | protein_coding |
| ENSDARG00000078859 | 4.727957055 | 1.46E-12 | protein_coding |
| MYRFL | -2.53518149 | 1.89E-12 | |
| ENSDARG00000087953 | 3.056798055 | 1.97E-12 | miRNA |
| ENSDARG00000089382 | 2.864534502 | 3.65E-12 | protein_coding |
| PDZRN3 | -2.361487556 | 5.04E-12 | |
| SLC16A1 | -2.31344781 | 6.27E-12 | |
| BMP10 | -2.566374785 | 7.56E-12 | |
| ENSDARG00000096403 | 2.7441639 | 7.94E-12 | lincRNA |
| ENSDARG00000070873 | 2.558192575 | 1.05E-11 | protein_coding |
| ENSDARG00000090733 | 2.774640053 | 1.83E-11 | miRNA |
| ENSDARG00000087337 | 2.801632112 | 1.98E-11 | miRNA |
| HEPACAM2 | 6.641683192 | 1.98E-11 | |
| ENSDARG00000017246 | -2.401867587 | 3.29E-11 | protein_coding |
| ENSDARG00000090146 | 2.984329301 | 4.74E-11 | miRNA |
| RBP4 | 2.002717065 | 6.27E-11 | |
| ENSDARG00000090175 | 2.882947206 | 6.63E-11 | miRNA |
| ENSDARG00000082789 | 2.100222947 | 8.53E-11 | Mt-tRNA |
| ENSDARG00000086192 | 3.098469469 | 1.09E-10 | miRNA |
| KCNMB2 | -2.581176089 | 1.79E-10 | |
| ENSDARG00000015815 | -1.809270076 | 2.43E-10 | protein_coding |
| NR4A1 | -2.146381259 | 3.12E-10 | |
| EPHB3 | -2.249748285 | 3.19E-10 | |
| SULT2B1 | 2.547289475 | 3.56E-10 | |
| ENSDARG00000058348 | 2.976849528 | 3.92E-10 | protein_coding |
| ENSDARG00000088311 | 2.795463059 | 4.35E-10 | miRNA |
| ETV4 | 2.433975283 | 5.45E-10 | |
| ENSDARG00000088838 | 2.703044112 | 5.80E-10 | miRNA |
| ENSDARG00000085168 | 6.285124238 | 6.35E-10 | miRNA |
| ENSDARG00000097100 | -2.044045148 | 6.70E-10 | protein_coding |
| ENSDARG00000087747 | 6.227650516 | 1.08E-09 | pseudogene |
| ENSDARG00000088582 | 6.225175014 | 1.09E-09 | pseudogene |
| LGR4 | -2.076095077 | 1.14E-09 | |

Table S3. Table showing the 50 most significant DE **non-coding RNAs**(miRNAs are highlighted in red) for the fused RNA-seq experiment: RNA-seq1 & RNA-seq2. The analysis was performed with Pathway Studio.